Generalized Anxiety Disorder
Conditions
Interventions
cTBS group:The coil positioned tangentially to the scalp on right dorsolateral prefrontal cortex, 600 pulses of cTBS with 100%RMT stimulation intensity for 40 s, a total of 10 treatments (twice a day
sham-cTBS group:The coil positioned 10 cm laterally above the scalp,the remaining treatment measures are the same as those of the cTBS group
Control group:None
Sponsors
Dalian Medical University Affiliated Second Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients with generalized anxiety disorder: (1) Age: 20-60 years old; (2) Meets the ICD-11 GAD diagnostic criteria; (3) Neuropsychological assessment showed positive anxiety symptoms (HAMA >= 14 points) but no significant depressive symptoms (17 HAMD <= 17 points); (4) All participants provided written informed consent. Inclusion criteria of the control group: (1) age: 20-60 years; (2) HAMA < 7 points and 17 HAMD < 7 points; (3) All participants provided written informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients with generalized anxiety disorder: (1) a history of major depression, bipolar disorder or schizophrenia; (2) a history of drug abuse and dependence in the past year; (3) use of benzodiazepines, which act on ?-aminobutyric acid-A (GABA-A) receptors; (4) having implantable metal devices in the body; (5) a history of central nervous system disease; having undergone craniocerebral operation; (6) a history of cardiovascular disease; (7)having received transcranial magnetic stimulation or electroconvulsive therapy in the previous year; (8) receiving psychotherapy or cognitive behavioural therapy during the study; (9) intolerance of the provided treatment. (10) pregnancy or lactation. Exclusion criteria of the control group: (1) a history of major depression, bipolar disorder or schizophrenia; (2) a history of central nervous system disease; having undergone craniocerebral operation; (3) a history of serious heart, liver, kidney and other important organ dysfunction, autoimmune diseases, hematological diseases and malignant tumors; (4) pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hamilton anxiety scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| hamilton depression scale;gamma aminobutyric acid;glutamate ;IL-1ß;IL-6;TNF-a; | — |
Countries
China
Contacts
Public ContactLin Yongzhong
Dalian Medical University Affiliated Second Hospital
Outcome results
None listed